Visus Therapeutics, a Seattle-based startup developing a presbyopia-correcting eye drop, raised $20 million. The fresh cash comes just six months after the company raised $36 million. Backers in this round include LSP, Sage Partners, Johnson & Johnson Innovation, and others. The company’s lead asset, BRIMOCHOL, is a once-daily eye drop that aims to treat presbyopia, a vision condition caused by aging that can make tasks such as reading difficult. It affects about 123 million adults in the U.S., according to the company. Existing treatments include glasses, contact lenses, or surgery. Founded in 2019, Visus is led by CEO Ben Bergo, who previously… Read More